Overview

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Status:
Terminated

Trial end date:
2017-06-21

Target enrollment:

Participant gender:

Summary

This Phase II study has been designed to evaluate the anti-tumor effects of adding OGX-427 to continuing abiraterone acetate and prednisone treatment in men with metastatic castrate-resistant prostate cancer (MCRPC) who have prostate-specific antigen (PSA) progression

Phase:

Phase 2

Details

Lead Sponsor:

Costantine Albany

Collaborators:

Achieve Life Sciences
Hoosier Cancer Research Network
OncoGenex Technologies

Treatments:

Abiraterone Acetate
Prednisone